NEW HAVEN, Conn., Dec. 15, 2015 /PRNewswire/ -- New Haven Pharmaceuticals, Inc. today announced President and CEO Patrick Fourteau was named a 2015 Entrepreneur of the Year award by Connecticut United for Research Excellence (CURE). Fourteau was recognized at a ceremony in Connecticut on Dec. 8th.
CURE is the bioscience cluster of Connecticut, a diverse network of small and large life and health care sciences companies, universities, scientists, educators, students, entrepreneurs, mentors, business experts, service providers and investors.
The award is given to innovators who meet the following criteria:
- demonstrated leadership in advancing the pursuit of scientific breakthroughs applied to real-world problems;
- built and funded a successful/disruptive business model for a company based in information technology, life, medical devices or healthcare sciences;
- made exceptional contributions to the growth of Connecticut's bioscience cluster;
- demonstrated collegiality, openness to mentoring and sharing of experiences and;
- whose contribution is visible outside of Connecticut
"Patrick is a visionary leader and motivator who also knows when to reshuffle the deck to make things work," said an industry expert familiar with his work through CURE. "Utilizing resources within Connecticut and elsewhere, he has led the company through its clinical trials, FDA approval and launch of DURLAZA, a breakthrough pharmaceutical product recently approved by the FDA."
The Entrepreneur of the Year Award began in 2013 to highlight imaginative, passionate and powerful individuals in the Connecticut area. Fourteau currently serves as leader in scientific breakthroughs, specifically in cardiovascular studies. His experience and dedication since 2011 has led New Haven Pharmaceuticals to advancements in business, medicine and health.
About New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals Inc. (www.newhavenpharma.com) is a specialty pharmaceuticals company developing new prescription drug products that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications representing attractive market opportunities. In addition to FDA-approved DURLAZA™, New Haven Pharmaceuticals is developing products incorporating proprietary Yale University technology utilizing zinc salts, including both a proprietary zinc salts product designed to lower stomach acid in patients suffering from gastro-esophageal reflux disease (or GERD) and a combination product with DURLAZA.
SOURCE New Haven Pharmaceuticals, Inc.